Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 12, Alnylam Pharmaceuticals reported its earnings for 2025, with nearly $3 billion in total revenue, which was an 81% increase year-over-year. Q4 was particularly strong, with net product revenue reaching $995 million, fueled by a 151% year-over-year surge in the TTR franchise following the successful launch of Amphotra for ATTR cardiomyopathy. In this quarter, Alnylam also launched ...